Rare bleeding disorder study seeks to unlock antibody mystery
NCT ID NCT04595617
First seen May 24, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This study looked at 28 people with Glanzmann thrombasthenia, a rare bleeding disorder, to understand why some develop harmful antibodies after blood transfusions or pregnancy. Researchers checked for antibodies every six months and after each transfusion over 18 months. The goal was to link genetic, treatment, and lifestyle factors to antibody formation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Bordeaux - Hôpital Haut-Lévêque
Bordeaux, France
-
CHU Bordeaux - Hôpital Pellegrin
Bordeaux, France
-
CHU Nîmes
Nîmes, France
-
CHU Strasbourg
Strasbourg, France
-
CHU Toulouse
Toulouse, France
-
Hôpital Bicêtre, APHP
Le Kremlin-Bicêtre, France
-
Hôpital la Timone, APHM
Marseille, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors predict and reduce the risk of antibody formation in Glanzmann thrombasthenia patients, improving transfusion safety.
What could go wrong
This is a small observational study (28 people) that only measures antibodies, not a treatment. It may not lead to direct changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.